Full Press Release Details
Media
• April 25, 2025
IRWD Positive Sentiment
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
Key Takeaway: Ironwood Pharmaceuticals has reaffirmed its full-year 2025 net sales guidance for LINZESS in the U.S. Additionally, the company has raised its adjusted EBITDA guidance, suggesting an optimistic financial outlook. This announcement reflects the company's confidence in the continued performance of LINZESS in the market.
Price reaction · baseline $0.8787 (2025-04-24 close) · hit after-hours · clean, no other IRWD news in the window
day 0 close
+1.1%
day 1 · peak
+10.4%
day 3
+6.1%
Market Sentiment Analysis
POSITIVE FACTORS
- Ironwood Pharmaceuticals maintains strong sales guidance for LINZESS.
- Adjusted EBITDA guidance has been raised, indicating financial growth.
- Positive outlook for 2025 reflects confidence in product performance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What is Ironwood's sales guidance for LINZESS in 2025?
Ironwood Pharmaceuticals has reiterated its full-year 2025 net sales guidance for LINZESS.
Has Ironwood adjusted its EBITDA guidance?
Yes, Ironwood has raised its adjusted EBITDA guidance, reflecting improved financial expectations.
What does the guidance indicate about LINZESS?
The guidance indicates strong market confidence in the continued performance of LINZESS.